search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Effect of N3-polyunsaturated fatty acids on peripheral insulin sensitivity.


- candidate number7931
- NTR NumberNTR2286
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR13-apr-2010
- Secondary IDsNL30857.018.10 / 10/001 ; CCMO / MEC
- Public TitleEffect of N3-polyunsaturated fatty acids on peripheral insulin sensitivity.
- Scientific TitleEffect of N3-polyunsaturated fatty acids on peripheral insulin sensitivity.
- ACRONYMFish Oil and Insulin Resistance
- hypothesis1. SMOFlipid® decreases peripheral insulin sensitivity to a lesser extent compared to the other lipid emulsions, Intralipid® and Clinoleic®, due to the lower n6/n3 ratio and the higher MCT concentration in the SMOFlipid emulsion;
2. SMOFlipid®, rich in specific N3-PUFA and MCT, affects not only the serum fatty acid composition but also the concentrations of bioactive lipids within skeletal muscle.
- Healt Condition(s) or Problem(s) studiedInsulin resistance, Trans parenteral nutrition
- Inclusion criteria1. Male;
2. BMI 20-25 kg/m2;
3. Stable weight during 3 months before participation and during participation;
4. Normal physical activity with at most 2 times per week sport activities;
5. Age 18-30;
6. Non-smoking;
7. Caucasian.
- Exclusion criteria1. Hypersensitivity to fish-, egg-, soya- or peanut protein;
2. Any medical condition or use of medication;
3. DM type II in first degree relatives;
4. Participation in other medical trial during the last 3 months.
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingNone
- controlPlacebo
- groupCrossover
- TypeSingle arm
- Studytypeintervention
- planned startdate 1-mei-2010
- planned closingdate1-mei-2011
- Target number of participants10
- InterventionsHyperinsulinemic euglycemic clamp with stable isotopes and concomitant infusion of a fish oil containing lipid emulsion, SMOFlipid®, on one occasion, and control saline infusion on the other occasion. Infusion will take 6 hours. FFA levels will be clamped at approximately 0.5 mmol/L. At the end of both clamps a muscle biopsy from the musculus vastus lateralis will be performed. Each participant will serve as its own control. Studies will be performed in balanced assignment.
- Primary outcomeTo study the acute effect of iv SMOFlipid® on peripheral glucose uptake in healthy humans.
- Secondary outcomeTo study the accumulation of FA metabolites and components of the insulin signaling pathway after infusion of SMOFlipid®.
- TimepointsEvery participant will serve as his own control and study days will be performed in random assignment. Both study days for one individual will be scheduled at least two weeks apart.
- Trial web siteN/A
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIES M. Brands
- CONTACT for SCIENTIFIC QUERIES M.J.M. Serlie
- Sponsor/Initiator Academic Medical Center (AMC), Department of Endocrinology and Metabolism
- Funding
(Source(s) of Monetary or Material Support)
Academic Medical Center (AMC), Department of Endocrinology and Metabolism
- PublicationsN/A
- Brief summaryFatty acids (FA) are no longer considered solely as a source of energy but also as potent regulators of intermediary metabolism. N3-poly unsaturated fatty acids (N3-PUFA) have been shown to be associated with a lower prevalence of cardiovascular diseases. FA are also involved in obesity induced insulin resistance and DM2. Saturated fatty acids are known for their negative interference on insulin stimulated glucose uptake in peripheral tissues. We recently studied the effect of two different intravenous lipid emulsions containing a mixture of MUFA, PUFA and saturated fatty acids on insulin sensitivity (MEC 05-295) and found insulin resistance but no difference between the two different lipid emulsions. Lipid emulsions for parenteral nutrition containing fish oil are now available. SMOFlipid emulsion is commercially available and based on 30% soy-bean oil, 30% medium chain triglycerides (MCT), 25% olive oil and 15% fish oil. We hypothesize that SMOFlipid® has a less profound effect on insulin sensitivity compared to the two earlier studied lipid emulsions.
- Main changes (audit trail)
- RECORD13-apr-2010 - 22-apr-2010


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl